Literature DB >> 29707728

Photoactivation of imatinib-antibody conjugate using low-energy visible light from Ru(ii)-polypyridyl cages.

Thomas N Rohrabaugh1, Ashley M Rohrabaugh, Jeremy J Kodanko, Jessica K White, Claudia Turro.   

Abstract

Ru(ii)-polypyridyl cages with sterically bulky bidentate ligands provide efficient photochemical release of the anticancer drug imatinib using low energy visible light, imparting spatiotemporal control over drug bioavailability. The light-activated drug release is maintained when the Ru(ii) cage is covalently coupled to an antibody, which is expected to localize selectively on the tumor.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29707728      PMCID： PMC6005383          DOI： 10.1039/c8cc01348a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  33 in total

1.  Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy.

Authors:  Jessica D Knoll; Claudia Turro
Journal:  Coord Chem Rev       Date:  2015-01-01       Impact factor: 22.315

Review 2.  Bioinorganic photochemistry: frontiers and mechanisms.

Authors:  Konrad Szaciłowski; Wojciech Macyk; Agnieszka Drzewiecka-Matuszek; Małgorzata Brindell; Grazyna Stochel
Journal:  Chem Rev       Date:  2005-06       Impact factor: 60.622

3.  Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine.

Authors:  Nicola J Farrer; Luca Salassa; Peter J Sadler
Journal:  Dalton Trans       Date:  2009-11-11       Impact factor: 4.390

Review 4.  Visible light photoredox catalysis with transition metal complexes: applications in organic synthesis.

Authors:  Christopher K Prier; Danica A Rankic; David W C MacMillan
Journal:  Chem Rev       Date:  2013-03-19       Impact factor: 60.622

5.  Quantum yield of singlet oxygen production by monomeric and aggregated forms of hematoporphyrin derivative.

Authors:  C Tanielian; C Schweitzer; R Mechin; C Wolff
Journal:  Free Radic Biol Med       Date:  2001-01-15       Impact factor: 7.376

Review 6.  Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib.

Authors:  Chandu M V de Silva; Robin Reid
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

7.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Inhibition of cathepsin activity in a cell-based assay by a light-activated ruthenium compound.

Authors:  Tomasz Respondek; Rajgopal Sharma; Mackenzie K Herroon; Robert N Garner; Jessica D Knoll; Eric Cueny; Claudia Turro; Izabela Podgorski; Jeremy J Kodanko
Journal:  ChemMedChem       Date:  2014-04-11       Impact factor: 3.466

9.  Unusually efficient pyridine photodissociation from Ru(II) complexes with sterically bulky bidentate ancillary ligands.

Authors:  Jessica D Knoll; Bryan A Albani; Christopher B Durr; Claudia Turro
Journal:  J Phys Chem A       Date:  2014-07-25       Impact factor: 2.781

10.  Combatting AMR: photoactivatable ruthenium(ii)-isoniazid complex exhibits rapid selective antimycobacterial activity.

Authors:  Nichola A Smith; Pingyu Zhang; Simon E Greenough; Michael D Horbury; Guy J Clarkson; Daniel McFeely; Abraha Habtemariam; Luca Salassa; Vasilios G Stavros; Christopher G Dowson; Peter J Sadler
Journal:  Chem Sci       Date:  2016-08-30       Impact factor: 9.825
View more
  5 in total

1.  Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia.

Authors:  John A Roque Iii; Houston D Cole; Patrick C Barrett; Liubov M Lifshits; Rachel O Hodges; Susy Kim; Gagan Deep; Antonio Francés-Monerris; Marta E Alberto; Colin G Cameron; Sherri A McFarland
Journal:  J Am Chem Soc       Date:  2022-04-28       Impact factor: 16.383

2.  Fine-Feature Modifications to Strained Ruthenium Complexes Radically Alter Their Hypoxic Anticancer Activity†.

Authors:  Houston D Cole; John A Roque; Liubov M Lifshits; Rachel Hodges; Patrick C Barrett; Dmytro Havrylyuk; David Heidary; Elamparuthi Ramasamy; Colin G Cameron; Edith C Glazer; Sherri A McFarland
Journal:  Photochem Photobiol       Date:  2021-03-28       Impact factor: 3.521

3.  Photocytotoxicity and photoinduced phosphine ligand exchange in a Ru(ii) polypyridyl complex.

Authors:  Sean J Steinke; Sayak Gupta; Eric J Piechota; Curtis E Moore; Jeremy J Kodanko; Claudia Turro
Journal:  Chem Sci       Date:  2022-02-01       Impact factor: 9.825

4.  Photorelease of a metal-binding pharmacophore from a Ru(II) polypyridine complex.

Authors:  Johannes Karges; Ryjul W Stokes; Seth M Cohen
Journal:  Dalton Trans       Date:  2021-03-02       Impact factor: 4.390

5.  Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.

Authors:  Nicholas Toupin; Sean J Steinke; Sandeep Nadella; Ao Li; Thomas N Rohrabaugh; Eric R Samuels; Claudia Turro; Irina F Sevrioukova; Jeremy J Kodanko
Journal:  J Am Chem Soc       Date:  2021-06-10       Impact factor: 16.383
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.